Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066359 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Myeloma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06066359 is a Phase 1 study of Myeloma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 44 participants, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06066359, a Phase 1 study of Myeloma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine phosphate
- DRUG NY-ESO-1 TCR/IL-15 NK
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06066359
The ClinicalTrials.gov registry entry for NCT06066359 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (55% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06066359 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06066359 about?
NCT06066359 is a clinical study titled "Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma". To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
What is the current status of trial NCT06066359?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-11-30. Estimated completion is 2028-08-31.
What conditions does trial NCT06066359 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT06066359?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine phosphate (DRUG), NY-ESO-1 TCR/IL-15 NK (DRUG).
Who is sponsoring clinical trial NCT06066359?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066359 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
-
Pilot Imaging Study of Leukemia
RECRUITING · Phase 1
-
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.